Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Zoledronic acid for prevention and treatment of osteoporosis.

Recknor C.

Expert Opin Pharmacother. 2011 Apr;12(5):807-15. doi: 10.1517/14656566.2011.562201. Review.

PMID:
21385149
2.

The role of zoledronic acid in the management of osteoporosis.

Maricic M.

Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Review.

PMID:
20544246
3.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
4.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.

Rheumatology (Oxford). 2013 Jun;52(6):1058-69. doi: 10.1093/rheumatology/kes410.

5.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652.

PMID:
18505912
6.

Role of zoledronic acid in the prevention and treatment of osteoporosis.

Räkel A, Boucher A, Ste-Marie LG.

Clin Interv Aging. 2011;6:89-99. doi: 10.2147/CIA.S7282. Review.

7.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

8.

Once-yearly zoledronic acid in hip fracture prevention.

Demontiero O, Duque G.

Clin Interv Aging. 2009;4:153-64. Review.

9.

Zoledronic acid infusion for prevention and treatment of osteoporosis.

Sunyecz JA.

Int J Womens Health. 2010 Oct 14;2:353-60. doi: 10.2147/IJWH.S7322.

10.

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.

Bone. 2012 Jan;50(1):289-95. doi: 10.1016/j.bone.2011.10.024. Erratum in: Bone. 2012 Mar;50(3):811.

PMID:
22061864
11.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
12.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.

Osteoporos Int. 2012 Mar;23(3):1083-90. doi: 10.1007/s00198-011-1800-1.

PMID:
21975559
14.

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Hamdy RC.

Drug Des Devel Ther. 2010 Nov 18;4:321-35. doi: 10.2147/DDDT.S6287. Review.

15.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8.

PMID:
17468062
16.

Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.

Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.

Intern Med J. 2011 Feb;41(2):186-90. doi: 10.1111/j.1445-5994.2010.02198.x.

PMID:
20214696
17.

Once-yearly zoledronic acid in older men compared with women with recent hip fracture.

Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial..

J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x.

PMID:
22091563
18.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial..

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765.

19.

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW.

J Am Geriatr Soc. 2010 Feb;58(2):292-9. doi: 10.1111/j.1532-5415.2009.02673.x.

20.

Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.

Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E.

Osteoporos Int. 2011 Aug;22(8):2337-45. doi: 10.1007/s00198-010-1448-2.

Items per page

Supplemental Content

Support Center